Sign in
Taking people in FrancePhase 3

Testing early steroids and rituximab for eye-onset myasthenia gravis in adults

Tests early steroids, adding rituximab if eye symptoms return, in adults with eye muscle myasthenia.

Key facts

Who runs it
Hopital Fondation Adolphe De Rothschild
Where
Bordeaux, Bron, Garches, Lille Cedex, Nice, Paris, Paris Cedex 13, Strasbourg Cedex 2, and Toulouse, FranceSee the 11 sites
Registry title
Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, randomized controlled trial
Status
Recruiting
Phase
Phase 3
People taking part
128 people, planned
Started
12 Feb 2025
Expected to end
3 Mar 2029
Type of study
Interventional
Record updated
6 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults recently diagnosed with myasthenia gravis that affects only the eyes, who have never had immune-suppressing treatment.

Age
Over 18 years
Sex
Women and men
Disease stage
Ocular myasthenia gravis diagnosed within the last 6 months, with symptoms only in the eye and eyelid muscles for at least one month.
Earlier treatment
No earlier immune-suppressing (immunosuppressive) treatment for ocular myasthenia gravis.
Biomarker or test result
Diagnosis needs typical eye signs (drooping eyelid or double vision that varies), or positive anti-AChR antibodies, or a positive nerve test or edrophonium test.

Main reasons for not taking part

  • Thymoma
  • Any infection, including hepatitis B
  • Pregnant or breast-feeding women
  • Eye symptoms that started more than one year before diagnosis
  • Past or current immune-suppressing treatment for a chronic illness

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Patients over 18 years old
  • Diagnosis of ocular myasthenia within the last 6 months, defined : either by a typical clinical examination objectified by an expert clinician: ptosis and/or binocular diplopia, with a variable and fluctuating character (either spontaneous or provoked by effort or rest) ; or by positive anti-AChR antibodies or the presence of a decrement on repetitive nerve stimulation or a positive edrophonium test
  • Myasthenic symptoms limited to ocular and/or orbicular muscles muscles (no non-ocular symptoms on MMS, MGC and MG-ADL)
  • Myasthenic symptoms for at least one month (to rule out generalized myasthenia at the outset)
  • Immunosuppressive therapy-naive management of ocular myasthenia gravis
  • Having received information about the study and having signed a consent to participate in the study
  • Affiliated to a social security system

Who cannot take part

  • Alternative diagnosis to ocular involvement (pupillary abnormality other than that resulting from previous local disease or surgery abduction myopathy due to dysthyroid ophthalmopathy or dysimmune orbitopathy)
  • Vaccination with live attenuated vaccine required during study and up to 6 months after rituximab discontinuation
  • Onset of ocular symptoms more than one year prior to diagnosis
  • Hyperuricemia on xanthine oxidase inhibitors (allopurinol and febuxostat)
  • Risk of urinary retention due to urethro-prostatic disorders
  • Persons deprived of their liberty by judicial or administrative administrative decision, persons under psychiatric care by virtue of articles L.3212-1 and L.3213-1 and persons admitted to a health or social establishment for purposes purposes other than research (L.1121-6)
  • History of immunosuppressive treatment or current immunosuppressive therapy for the management of a chronic pathology
  • Hypersensitivity to paracetamol
  • Hypersensitivity to rituximab or murine proteins
  • Hypersensitivity to prednisone and/or methylprednisone
  • Hypersensitivity to aziathioprine or 6-mercaptopurine
  • Hypersensitivity to dexchlorpheniramine
  • Any infectious condition (including hepatitis b)
  • Severe heart failure (New York Heart Association (NYHA) Class IV) or severe uncontrolled heart disease
  • Severe liver failure
  • Women of childbearing age* who do not wish to use effective contraception (effective contraception includes oral contraception, intrauterine devices and other forms of contraception with a failure rate <1%) during their participation and at least 12 months after the last dose (oral commitment by the patient recorded in the file by the investigator)
  • Thymoma
  • Risk of angle-closure glaucoma
  • Pregnant or breast-feeding women
  • Adults under legal protection (L.1121-8)
  • Patients with severe immune deficiency
  • Psychotic state not yet controlled by treatment

Where in France

  • Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
  • Hospices Civils de LyonBron, FranceTaking people
  • Assistance Publique Hopitaux De ParisGarches, FranceTaking people
  • Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
  • Centre Hospitalier Universitaire de NiceNice, FranceTaking people
  • Centre Hospitalier Sainte Anne ParisParis, FranceTaking people
  • Hopital Fondation Adolphe de RothschildParis, FranceTaking people
  • Quinze-Vingts National Ophthalmology HospitalParis, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 13, FranceTaking people
  • Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceTaking people
  • Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people

About the trial

What the trial wants to find out

To evaluate, in patients with ocular-onset myasthenia gravis, the effect of a standardized proactive strategy combining immediate treatment with corticosteroids at the time of diagnosis and the addition of rituximab in the event of recurrence of ocular symptoms during corticosteroid taper, on generalization at 2 years.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, randomized controlled trial
Plain-language title
Testing early steroids and rituximab for eye-onset myasthenia gravis in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
6 June 2025